© 2022 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Astralis Ltd., partnered with SkyPharma PLC, has initiated a phase I clinical trial in the United States for Psoraxine, a new injectable treatment for moderate psoriasis.